CASE STUDY

Creation of Global Value Dossiers for a US-based Global Pharmaceutical Company
Febrile Neutropenia (FN) during adjuvant chemotherapy is associated with significant morbidity, mortality risk, and incremental costs. The client wanted a vendor to develop content for a Global Value Dossier (GVD) about the burden of febrile neutropenia during adjuvant chemotherapy.

After evaluating the evidence requirements outlined by the AMCP, our GVD team created a table of contents along with a draft outline. In parallel, we identified search terms and developed search strings to extensively search free and syndicated databases for relevant published literature. After a thorough screening of the parsed literature, relevant articles were selected. Our experts summarized data for the clinical and economic burden of FN during adjuvant chemotherapy and prepared a draft for the client’s perusal. Based on the client’s inputs and the AMCP guidelines, all documents were edited. In the final stage of the project, our team developed submission-ready reference masters and supporting documentation.

The developed content was used to formulate a GVD that was submitted to the payer bodies. The GVD was successfully communicated the product value and the client’s drug was recommended for formulary listing after a Health Technology Assessment (HTA).

Insights: Our experts are fully equipped to develop any type of technical document. Pharmaceutical, biotechnology, and medical device companies trust our services because of experience and our attitude. The commitment and dedication of our team ensures that every customer is satisfied.